ArticleOncotarget2017

CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients.

Yifan Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.